

CORRECTION

Open Access



Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials

Timothy R. Smith^{1*}, Egilius L. H. Spierings², Roger Cady³, Joe Hirman⁴, Barbara Schaeffler⁵, Vivienne Shen⁶, Bjørn Sperling⁷, Thomas Brevig⁷, Mette Krog Josiassen⁷, Elizabeth Brunner⁶, Loan Honeywell⁷ and Lahar Mehta⁵

Correction to: J Headache Pain 22, 16 (2021)
<https://doi.org/10.1186/s10194-021-01227-5>

Following the publication of the original article [1], the authors notified us of a few data points that require revision (marked in red below):

Incorrect:

- Nearly one-third (32.4%) of all patients were classified as obese (BMI ≥ 30 kg/m²), and nearly half (48.9%) had at least 1 cardiovascular risk factor at baseline.
- “Blood pressure increased” was noted for 39/2076 (1.9%) patients who received eptinezumab and 14/791 (1.8%) patients who received placebo, ...

Correct:

- Nearly one-third (32.4%) of all patients were classified as obese (BMI ≥ 30 kg/m²), and nearly half (48.8%) had at least 1 cardiovascular risk factor at baseline.
- “Blood pressure increased” was noted for 14/2076 (0.7%) patients who received eptinezumab and 5/791 (0.6%) patients who received placebo, ...

The original article has been corrected.

Author details

¹StudyMetrix Research, LLC, 3862 Mexico Road, St. Peters, MO 63303, USA. ²Medvadis Research Corporation, Boston PainCare, Waltham, MA, USA. ³Lundbeck La Jolla Research Center, San Diego, CA, USA. ⁴Pacific Northwest Statistical Consulting, Inc, Woodinville, WA, USA. ⁵Lundbeck Seattle BioPharmaceuticals, Inc, Seattle, WA, USA. ⁶Lundbeck LLC, Deerfield, IL, USA. ⁷H. Lundbeck A/S, Copenhagen, Denmark.

Published online: 25 May 2021

Reference

1. Smith et al (2021) Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. *J Headache Pain* 22:16. <https://doi.org/10.1186/s10194-021-01227-5>

The original article can be found online at <https://doi.org/10.1186/s10194-021-01227-5>.

* Correspondence: tsmith@studymetrix.com

¹StudyMetrix Research, LLC, 3862 Mexico Road, St. Peters, MO 63303, USA

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.